Cytovance Biologics

Cytovance Biologics is a leading player in the biotechnology and manufacturing industries. Established in 2003, the company prides itself on being a responsive, reliable, and resourceful partner in the contract development and manufacturing (CDMO) landscape. With a strong emphasis on advancing the commercialization of biologics, Cytovance Biologics offers expertise in microbial and mammalian expression systems for scale-up at every stage, from cell line development to cGMP manufacturing. The company's track record speaks volumes, with a remarkable 95% scale-up success rate and a focus on quality, scalability, and reproducibility. Cytovance Biologics specializes in a wide range of therapeutic proteins and antibodies, including biosimilars, cytokines, enzymes/hormones, fusion proteins, bispecific, fragment, and monoclonal antibodies, recombinant proteins, vaccines, and more. In terms of investment, the company secured a significant $20.00M Debt Financing investment from Monroe Capital on 28 October 2014, underlining investor confidence in the company's potential for growth and success. Cytovance Biologics' commitment to delivering innovative solutions and guiding assets through the complexities of manufacturing positions it as a strong contender in the biopharmaceutical market.